“This leaves adherence – getting patients to stay on their prescribed therapy – as the final financial frontier for the pharmaceutical industry …”
This is a fantastic article that helps articulate the enormous value that currently exists with medication adherence. For example, the article stipulates that Pharmaceutical companies lose an estimated $637 billion globally and $250 billion in the US each year from medication (non)adherence. It estimates that some current education-based adherence programs applied at scale could contribute up to a 30 percent increase in annual earnings per share for some companies, with other research suggesting current adherence programs can deliver an average of $2 billion in additional revenue per year for each of the 21 pharmaceutical companies assessed.
You can find a link to the article here.